Acumen announces $35.75M private placement

Acumen (ABOS) Pharmaceuticals has entered into a securities purchase agreement with certain institutional and accredited investors for a private placement of approximately $35.75 million of shares of its common stock at a price of $3.30 per share. Acumen expects to receive gross proceeds from the offering of approximately $35.75 million, before deducting offering expenses. The private placement was led by existing investor RA Capital Management, with participation from other investors, including ADAR1 Capital Management, Sands Capital, and a large investment management firm. The private placement is expected to close on or about March 16, 2026, subject to the satisfaction of customary closing conditions.